Search

Your search keyword '"Yoshihama, Tomoko"' showing total 11 results
Start Over Author "Yoshihama, Tomoko" Search Limiters Full Text
11 results on '"Yoshihama, Tomoko"'

6. Germline multigene panel testing revealed a BRCA2 pathogenic variant in a patient with suspected Lynch syndrome

Author

Yoshihama, Tomoko, primary, Hirasawa, Akira, additional, Sugano, Kokichi, additional, Yoshida, Teruhiko, additional, Ushiama, Mineko, additional, Ueki, Arisa, additional, Akahane, Tomoko, additional, Nanki, Yoshiko, additional, Sakai, Kensuke, additional, Makabe, Takeshi, additional, Yamagami, Wataru, additional, Susumu, Nobuyuki, additional, Kameyama, Kaori, additional, Kosaki, Kenjiro, additional, and Aoki, Daisuke, additional

Published
2020
Full Text
View/download PDF

7. A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer

Author

Nanki, Yoshiko, primary, Nomura, Hiroyuki, additional, Iwasa, Naomi, additional, Saotome, Keiko, additional, Dozen, Ai, additional, Yoshihama, Tomoko, additional, Hirano, Takuro, additional, Hashimoto, Shiho, additional, Chiyoda, Tatsuyuki, additional, Yamagami, Wataru, additional, Kataoka, Fumio, additional, and Aoki, Daisuke, additional

Published
2020
Full Text
View/download PDF

9. GSTP1rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes

Author

Yoshihama, Tomoko, primary, Fukunaga, Koya, additional, Hirasawa, Akira, additional, Nomura, Hiroyuki, additional, Akahane, Tomoko, additional, Kataoka, Fumio, additional, Yamagami, Wataru, additional, Aoki, Daisuke, additional, and Mushiroda, Taisei, additional

Published
2018
Full Text
View/download PDF

11. GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes.

Author

Yoshihama T, Fukunaga K, Hirasawa A, Nomura H, Akahane T, Kataoka F, Yamagami W, Aoki D, and Mushiroda T

Abstract

Purpose: To find genetic variants that predicted toxicity and/or efficacy of paclitaxel plus carboplatin combination therapy (TC therapy)., Patients and Methods: In a retrospective case-control study, we analyzed 320 patients who had received TC therapy for gynecological cancers (ovarian, fallopian tube, peritoneal, uterine, and cervical cancers) and collected their germline DNA. We performed a comprehensive pharmacogenomic analysis using a targeted resequencing panel of 100 pharmacogenes. For 1,013 variants passing QC, case-control association studies and survival analyses were conducted., Results: GSTP1 rs1695 showed the smallest p value for hematotoxicity association, and the 105 Ile wild type allele had a significantly higher risk of severe hematotoxicity (neutropenia G4, thrombocytopenia ≥ G3 and anemia ≥ G3) than the 105 Val allele (p=0.00034, odds ratio=5.71 (95% confidence interval:1.77-18.44)). Next, we assessed 5-year progression-free survival (PFS) and overall survival (OS) in 56 advanced ovarian cancer patients who received tri-weekly TC as a first-line chemotherapy. Patients with the 105 Ile/ 105 Ile genotype showed significantly better PFS (p=0.00070) and OS (p=0.0012) than those with the 105 Ile/ 105 Val or 105 Val/ 105 Val genotype., Conclusion: Our study indicates that the GSTP1 rs1695 105 Ile/ 105 Ile genotype is associated with both severe hematotoxicity and high efficacy of TC therapy, identifying a possible prognostic indicator for patients with TC therapy., Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results